The Triapartit agreement is intended in the event that the sponsor`s management of a commercial clinical trial is outsourced to a contract research organization. CRO mCIA is supported by the UK Health Services, the National Institute for Health Research, the Association of British Healthcare Industries, the NHS Confederation, the Medical Schools Council, the UK Clinical Research Collaboration, the NHS Research Forum and the Institute for Clinical Research. The model is structured to meet the requirements of non-commercial sponsors and NHS (or other) research organizations, and has been developed as a single UK agreement model, meaning it can be used regardless of where the sponsor and search website are established. National site location agreements help speed up the process of awarding trials in the NHS supported by industry, as there is no longer a need for site-by-site controls and local legal agreements. This allows studies to start earlier, improve the speed of industry-sponsored clinical trials and enable patients with NHS to access innovative treatments more quickly. The range of model location agreements is supported by guidelines that specify the objectives and modalities of the use of the agreement in the development of clinical research contracts supported by pharmaceutical, biopharmaceutical or medical companies. Primary Care mCTA was designed to simplify and expedite the process of stopping and initiating pharmaceutical and biopharmaceutical clinical trials on primary care patients. The intention is that the mCTA Primary Care Centre will be used regularly without modification by all promoters of the pharmaceutical and biopharmaceutical industry of contract clinical research, where patients with NHS are recruited into primary care. In such cases, no further legal review is required, saving money and time. Launched in February 2011, the Model Industry Collaborative Research Agreement (MICRA) aims to support cooperation in clinical research involving the pharmaceutical and biotechnology industries, universities and NHS organisations in the UK. „The revised MNCA should be used in place of the previous version 1.0, as it contains key clauses to bring it into compliance with the RGPD, and we will soon publish further guidelines on adapting existing agreements to the regulation. It is rare that a formal agreement is not necessary; (z.B.
some of the non-commercial studies for which the proponent may make a „declaration of activity“ in lieu of a formal agreement. MICRA was developed by a working group led by the NIHR Office for Clinical Research Infrastructure (NOCRI) and the Medical Research Council. Representatives from industry, universities, the NHS and the Intellectual Property Office worked with legal opinions to develop a model agreement that could support all collaborative research scenarios. Organizations participating in the working group agreed on a statement of support in which they encouraged their use to streamline the collaborative research allocation process. The revised models for February 2018 of the Clinical Trial Agreement (mCTA) and the Clinical Research Organisation model Clinical Trial Agreement (CRO-mCTA) are designed to be used without modification for industry-sponsored studies of patients with NHS/HSC in hospitals across the UK health service.